Mayne Pharma (MYX AU): Scheme Booklet Dispatch Lends More Than A Veneer Of Support
After a rough week - somewhat of an understatement - the Scheme Doc is now out.
The Court Meeting is the18th June; the last day of trading the 23rd June, and implementation 2nd July. The IE says fair with a valuation range of A$6.61-A$7.99/share.
This IE's valuation range doesn't factor in the pharma EO, given its ambiguity. Nor the FDA level. However, Mayne, ASIC AND Cosette have effectively signed off on the Doc's veracity.
Keep reading with a 7-day free trial
Subscribe to Aussie/Kiwi M&A/Events to keep reading this post and get 7 days of free access to the full post archives.